Answers are grounded in this paper and cite their sources.
Minor drug-resistant cell populations can emerge during therapy and drive relapse in neuroblastoma, yet methods to define these cells remain limited. We generated longitudinal single-cell transcriptomes from tumors collected at diagnosis (Dx), post-chemotherapy (Rx), and relapse (Rel) in 10 children with high-risk disease. Across 26 samples (152,366 cells), we identified 80,678 malignant sympathetic tumor cells. Patient-specific pseudotime and trajectory analyses revealed transcriptional programs linked to resistance, including upregulation of stathmin 1 (STMN1) and Aly/REF export factor (ALYREF). Functional knockdown sensitized neuroblastoma cells to chemotherapy. Pathway analyses identified Hedgehog signaling as a recurrent driver of drug tolerance, potentially mediated by tumor-associated Schwann cells. Pharmacological inhibition of this pathway restored chemotherapy sensitivity in vitro and in vivo . Post-treatment tumors also showed enrichment of the pro-inflammatory proteoglycan serglycin (SRGN), highlighting a potential treatment-associated biomarker. Together, these findings demonstrate that longitudinal single-cell profiling can uncover patient-specific resistance mechanisms and actionable therapeutic vulnerabilities in neuroblastoma.
No takes yet. Share an insight, caveat, or question.
Seneviratne et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: